Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515702 | 0.82 | TRPM8 (0.35) | MEN1USP2KMT2AKDM4EDPP4 | |
| SCHEMBL516132 | 0.82 | CYP3A4 (0.52) | GPR88MEN1USP2KMT2AKDM4E | |
| SCHEMBL516121 | 0.79 | KDM4E (0.42) | GPR88MEN1KMT2AKDM4EDPP4 | |
| SCHEMBL515694 | 0.78 | ALDH1A1 (0.43) | OPRM1ALDH1A1 | |
| SCHEMBL515952 | 0.76 | POLB (0.43) | OPRM1GPR88 | |
| SCHEMBL516145 | 0.75 | SLC6A2 (0.39) | OPRM1GPR88USP2KDM4EALDH1A1 | |
| SCHEMBL516778 | 0.74 | HPGD (0.42) | GPR88MEN1KMT2AALDH1A1 | |
| SCHEMBL14760360 | 0.73 | CYP3A4 (0.58) | GPR88MEN1USP2KMT2A | |
| SCHEMBL516110 | 0.73 | OPRM1 (0.43) | OPRM1ALDH1A1 | |
| SCHEMBL515948 | 0.73 | SLC6A2 (0.41) | OPRM1GPR88MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | claimed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | claimed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | claimed |
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | disclosed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | disclosed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | CYP11B2, BCAT1, CYP11B1 | MC4R 1895/4885OPRM1 338/4885GPR88 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.